These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 22420529)

  • 1. Eliciting cross-neutralizing antibodies in mice challenged with a dengue virus envelope domain III expressed in Escherichia coli.
    Yang J; Zhang J; Chen W; Hu Z; Zhu J; Fang X; Yuan W; Li M; Hu X; Tan Y; Hu F; Rao X
    Can J Microbiol; 2012 Apr; 58(4):369-80. PubMed ID: 22420529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting of envelope domain III protein of DENV type 2 to DEC-205 receptor elicits neutralizing antibodies in mice.
    Coconi-Linares N; Ortega-Dávila E; López-González M; García-Machorro J; García-Cordero J; Steinman RM; Cedillo-Barrón L; Gómez-Lim MA
    Vaccine; 2013 May; 31(19):2366-71. PubMed ID: 23499580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies.
    Poddar A; Ramasamy V; Shukla R; Rajpoot RK; Arora U; Jain SK; Swaminathan S; Khanna N
    BMC Biotechnol; 2016 Jun; 16(1):50. PubMed ID: 27301568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dengue virus envelope domain III immunization elicits predominantly cross-reactive, poorly neutralizing antibodies localized to the AB loop: implications for dengue vaccine design.
    Li XQ; Qiu LW; Chen Y; Wen K; Cai JP; Chen J; Pan YX; Li J; Hu DM; Huang YF; Liu LD; Ding XX; Guo YH; Che XY
    J Gen Virol; 2013 Oct; 94(Pt 10):2191-2201. PubMed ID: 23851440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2.
    Arora U; Tyagi P; Swaminathan S; Khanna N
    J Nanobiotechnology; 2012 Jul; 10():30. PubMed ID: 22794664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dimerization of Dengue Virus E Subunits Impacts Antibody Function and Domain Focus.
    Thomas A; Thiono DJ; Kudlacek ST; Forsberg J; Premkumar L; Tian S; Kuhlman B; de Silva AM; Metz SW
    J Virol; 2020 Aug; 94(18):. PubMed ID: 32611757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.
    Frei JC; Wirchnianski AS; Govero J; Vergnolle O; Dowd KA; Pierson TC; Kielian M; Girvin ME; Diamond MS; Lai JR
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic Cell Targeting Using a DNA Vaccine Induces Specific Antibodies and CD4
    Zaneti AB; Yamamoto MM; Sulczewski FB; Almeida BDS; Souza HFS; Ferreira NS; Maeda DLNF; Sales NS; Rosa DS; Ferreira LCS; Boscardin SB
    Front Immunol; 2019; 10():59. PubMed ID: 30761131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity.
    Khanam S; Pilankatta R; Khanna N; Swaminathan S
    Vaccine; 2009 Oct; 27(43):6011-21. PubMed ID: 19665609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice.
    Arora U; Tyagi P; Swaminathan S; Khanna N
    Vaccine; 2013 Jan; 31(6):873-8. PubMed ID: 23261049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice.
    Ramasamy V; Arora U; Shukla R; Poddar A; Shanmugam RK; White LJ; Mattocks MM; Raut R; Perween A; Tyagi P; de Silva AM; Bhaumik SK; Kaja MK; Villinger F; Ahmed R; Johnston RE; Swaminathan S; Khanna N
    PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006191. PubMed ID: 29309412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine.
    Galula JU; Shen WF; Chuang ST; Chang GJ; Chao DY
    J Virol; 2014 Sep; 88(18):10813-30. PubMed ID: 25008922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human monoclonal single-chain antibodies specific to dengue virus envelope protein.
    Saokaew N; Poungpair O; Panya A; Tarasuk M; Sawasdee N; Limjindaporn T; Chaicumpa W; Yenchitsomanus P
    Lett Appl Microbiol; 2014 Mar; 58(3):270-7. PubMed ID: 24266517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dengue virus envelope protein domain III-elicited antibodies mediate cross-protection against Zika virus in a mouse model.
    Zhou Y; Chen D; Yang L; Zou W; Duan Z; Zhang Y; Wen J
    Virus Res; 2020 Mar; 278():197882. PubMed ID: 31981774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pichia pastoris-expressed dengue virus type 2 envelope domain III elicits virus-neutralizing antibodies.
    Batra G; Raut R; Dahiya S; Kamran N; Swaminathan S; Khanna N
    J Virol Methods; 2010 Jul; 167(1):10-6. PubMed ID: 20211204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mapping of the B Cell Neutralizing Epitopes on ED III of Envelope Protein from Dengue Virus].
    Lin Y; Wen K; Guo Y; Qiu L; Pan Y; Yu L; Di B; Chen Y
    Bing Du Xue Bao; 2015 Nov; 31(6):665-73. PubMed ID: 26951013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo.
    Williams KL; Wahala WM; Orozco S; de Silva AM; Harris E
    Virology; 2012 Jul; 429(1):12-20. PubMed ID: 22537810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of neutralizing antibodies against four serotypes of dengue viruses by MixBiEDIII, a tetravalent dengue vaccine.
    Zhao H; Jiang T; Zhou XZ; Deng YQ; Li XF; Chen SP; Zhu SY; Zhou X; Qin ED; Qin CF
    PLoS One; 2014; 9(1):e86573. PubMed ID: 24466156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of Surface Display of DENV2 E Protein on a Nanoparticle to Induce Virus Specific Neutralizing Antibody Responses.
    Coffman JE; Metz SW; Brackbill A; Paul M; Miley MJ; DeSimone J; Luft JC; de Silva A; Tian S
    Bioconjug Chem; 2018 May; 29(5):1544-1552. PubMed ID: 29701995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural and Functional Characterization of a Cross-Reactive Dengue Virus Neutralizing Antibody that Recognizes a Cryptic Epitope.
    Li J; Watterson D; Chang CW; Che XY; Li XQ; Ericsson DJ; Qiu LW; Cai JP; Chen J; Fry SR; Cheung STM; Cooper MA; Young PR; Kobe B
    Structure; 2018 Jan; 26(1):51-59.e4. PubMed ID: 29249606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.